Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells

Annabell S. Oh, Lori A. Lorant, Jamie N. Holloway, David L. Miller, Francis G. Kern, Dorraya El-Ashry

Research output: Contribution to journalArticle

205 Citations (Scopus)

Abstract

ERα-negative breast tumors tend to overexpress growth factor receptors such as epidermal growth factor receptor or c-erbB-2. Raf-1 is a key intermediate in the signal transduction pathways of these receptors. High levels of constitutive Raf kinase (Δraf) activity imparts ERα- positive MCF-7 breast cancer cells with the ability to grow in the absence of estrogen. Δraf transfectants maintained in estrogen-depleted media showed greatly diminished responses to 17β-estradiol or the pure antiestrogen ICI 182,780. Western blotting, ligand binding, and immunohistochemistry assays revealed a loss of ERα protein expression, and ribonuclease protection assays indicated that this correlated with loss of ERα message. In examining the basal expression of estrogen-induced genes in the stable transfectants or in transient cotransfection assays with an estrogen-response element-reporter construct and Δraf or constitutively active MAPK kinase (ΔMEK), no ligand- independent activation of ERα was observed. Transient expression of Δraf and double-label immunostaining showed ERα was lost in those cells that transiently expressed Δraf. Abrogation of Raf signaling via treatment with the MEK inhibitors PD 098059 or U0126 resulted in reexpression of ERα. Similar studies performed with MCF-7 cells overexpressing epidermal growth factor receptor or c-erbB-2 confirmed that hyperactivation of MAPK resulted in down-regulation of ERα that was reversible by MEK inhibition or transfection with dominant negative ERK1 and ERK2 constructs. These data suggest that the hyperactivation of MAPK in epidermal growth factor receptor- or c-erbB-2-overexpressing breast cancer cells is directly responsible for generation of an ERα-negative phenotype and, more importantly, that this process may be abrogated by inhibiting these pathways, thus restoring ERα expression.

Original languageEnglish
Pages (from-to)1344-1359
Number of pages16
JournalMolecular Endocrinology
Volume15
Issue number8
DOIs
StatePublished - Aug 14 2001
Externally publishedYes

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Estrogens
Epidermal Growth Factor Receptor
Breast Neoplasms
raf Kinases
Ligands
Estrogen Receptor Modulators
Growth Factor Receptors
MCF-7 Cells
Response Elements
Ribonucleases
Transfection
Estradiol
Signal Transduction
Down-Regulation
Western Blotting
Immunohistochemistry
Phenotype
Genes
Proteins

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology, Diabetes and Metabolism

Cite this

Oh, A. S., Lorant, L. A., Holloway, J. N., Miller, D. L., Kern, F. G., & El-Ashry, D. (2001). Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Molecular Endocrinology, 15(8), 1344-1359. https://doi.org/10.1210/me.15.8.1344

Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. / Oh, Annabell S.; Lorant, Lori A.; Holloway, Jamie N.; Miller, David L.; Kern, Francis G.; El-Ashry, Dorraya.

In: Molecular Endocrinology, Vol. 15, No. 8, 14.08.2001, p. 1344-1359.

Research output: Contribution to journalArticle

Oh, AS, Lorant, LA, Holloway, JN, Miller, DL, Kern, FG & El-Ashry, D 2001, 'Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells', Molecular Endocrinology, vol. 15, no. 8, pp. 1344-1359. https://doi.org/10.1210/me.15.8.1344
Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Molecular Endocrinology. 2001 Aug 14;15(8):1344-1359. https://doi.org/10.1210/me.15.8.1344
Oh, Annabell S. ; Lorant, Lori A. ; Holloway, Jamie N. ; Miller, David L. ; Kern, Francis G. ; El-Ashry, Dorraya. / Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. In: Molecular Endocrinology. 2001 ; Vol. 15, No. 8. pp. 1344-1359.
@article{bb7d05f1798f4216855f557fa37813b9,
title = "Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells",
abstract = "ERα-negative breast tumors tend to overexpress growth factor receptors such as epidermal growth factor receptor or c-erbB-2. Raf-1 is a key intermediate in the signal transduction pathways of these receptors. High levels of constitutive Raf kinase (Δraf) activity imparts ERα- positive MCF-7 breast cancer cells with the ability to grow in the absence of estrogen. Δraf transfectants maintained in estrogen-depleted media showed greatly diminished responses to 17β-estradiol or the pure antiestrogen ICI 182,780. Western blotting, ligand binding, and immunohistochemistry assays revealed a loss of ERα protein expression, and ribonuclease protection assays indicated that this correlated with loss of ERα message. In examining the basal expression of estrogen-induced genes in the stable transfectants or in transient cotransfection assays with an estrogen-response element-reporter construct and Δraf or constitutively active MAPK kinase (ΔMEK), no ligand- independent activation of ERα was observed. Transient expression of Δraf and double-label immunostaining showed ERα was lost in those cells that transiently expressed Δraf. Abrogation of Raf signaling via treatment with the MEK inhibitors PD 098059 or U0126 resulted in reexpression of ERα. Similar studies performed with MCF-7 cells overexpressing epidermal growth factor receptor or c-erbB-2 confirmed that hyperactivation of MAPK resulted in down-regulation of ERα that was reversible by MEK inhibition or transfection with dominant negative ERK1 and ERK2 constructs. These data suggest that the hyperactivation of MAPK in epidermal growth factor receptor- or c-erbB-2-overexpressing breast cancer cells is directly responsible for generation of an ERα-negative phenotype and, more importantly, that this process may be abrogated by inhibiting these pathways, thus restoring ERα expression.",
author = "Oh, {Annabell S.} and Lorant, {Lori A.} and Holloway, {Jamie N.} and Miller, {David L.} and Kern, {Francis G.} and Dorraya El-Ashry",
year = "2001",
month = "8",
day = "14",
doi = "10.1210/me.15.8.1344",
language = "English",
volume = "15",
pages = "1344--1359",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells

AU - Oh, Annabell S.

AU - Lorant, Lori A.

AU - Holloway, Jamie N.

AU - Miller, David L.

AU - Kern, Francis G.

AU - El-Ashry, Dorraya

PY - 2001/8/14

Y1 - 2001/8/14

N2 - ERα-negative breast tumors tend to overexpress growth factor receptors such as epidermal growth factor receptor or c-erbB-2. Raf-1 is a key intermediate in the signal transduction pathways of these receptors. High levels of constitutive Raf kinase (Δraf) activity imparts ERα- positive MCF-7 breast cancer cells with the ability to grow in the absence of estrogen. Δraf transfectants maintained in estrogen-depleted media showed greatly diminished responses to 17β-estradiol or the pure antiestrogen ICI 182,780. Western blotting, ligand binding, and immunohistochemistry assays revealed a loss of ERα protein expression, and ribonuclease protection assays indicated that this correlated with loss of ERα message. In examining the basal expression of estrogen-induced genes in the stable transfectants or in transient cotransfection assays with an estrogen-response element-reporter construct and Δraf or constitutively active MAPK kinase (ΔMEK), no ligand- independent activation of ERα was observed. Transient expression of Δraf and double-label immunostaining showed ERα was lost in those cells that transiently expressed Δraf. Abrogation of Raf signaling via treatment with the MEK inhibitors PD 098059 or U0126 resulted in reexpression of ERα. Similar studies performed with MCF-7 cells overexpressing epidermal growth factor receptor or c-erbB-2 confirmed that hyperactivation of MAPK resulted in down-regulation of ERα that was reversible by MEK inhibition or transfection with dominant negative ERK1 and ERK2 constructs. These data suggest that the hyperactivation of MAPK in epidermal growth factor receptor- or c-erbB-2-overexpressing breast cancer cells is directly responsible for generation of an ERα-negative phenotype and, more importantly, that this process may be abrogated by inhibiting these pathways, thus restoring ERα expression.

AB - ERα-negative breast tumors tend to overexpress growth factor receptors such as epidermal growth factor receptor or c-erbB-2. Raf-1 is a key intermediate in the signal transduction pathways of these receptors. High levels of constitutive Raf kinase (Δraf) activity imparts ERα- positive MCF-7 breast cancer cells with the ability to grow in the absence of estrogen. Δraf transfectants maintained in estrogen-depleted media showed greatly diminished responses to 17β-estradiol or the pure antiestrogen ICI 182,780. Western blotting, ligand binding, and immunohistochemistry assays revealed a loss of ERα protein expression, and ribonuclease protection assays indicated that this correlated with loss of ERα message. In examining the basal expression of estrogen-induced genes in the stable transfectants or in transient cotransfection assays with an estrogen-response element-reporter construct and Δraf or constitutively active MAPK kinase (ΔMEK), no ligand- independent activation of ERα was observed. Transient expression of Δraf and double-label immunostaining showed ERα was lost in those cells that transiently expressed Δraf. Abrogation of Raf signaling via treatment with the MEK inhibitors PD 098059 or U0126 resulted in reexpression of ERα. Similar studies performed with MCF-7 cells overexpressing epidermal growth factor receptor or c-erbB-2 confirmed that hyperactivation of MAPK resulted in down-regulation of ERα that was reversible by MEK inhibition or transfection with dominant negative ERK1 and ERK2 constructs. These data suggest that the hyperactivation of MAPK in epidermal growth factor receptor- or c-erbB-2-overexpressing breast cancer cells is directly responsible for generation of an ERα-negative phenotype and, more importantly, that this process may be abrogated by inhibiting these pathways, thus restoring ERα expression.

UR - http://www.scopus.com/inward/record.url?scp=0034899503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034899503&partnerID=8YFLogxK

U2 - 10.1210/me.15.8.1344

DO - 10.1210/me.15.8.1344

M3 - Article

C2 - 11463858

AN - SCOPUS:0034899503

VL - 15

SP - 1344

EP - 1359

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 8

ER -